Vir Biotechnology has concluded an exclusive worldwide licence agreement with Sanofi, enabling access to multiple clinical-stage T-cell engagers (TCEs) and the PRO-XTEN masking platform. The deal ...

Vir Biotechnology, Inc. today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers: VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting ...

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell ...

Vir Biotechnology (VIR) is presenting initial Phase 1 data from two of its dual-masked T-cell engagers: VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the fourth quarter and full ...